tadalafil has been researched along with Lower Urinary Tract Symptom in 117 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 84 (71.79) | 24.3611 |
| 2020's | 33 (28.21) | 2.80 |
| Authors | Studies |
|---|---|
| Ashida, S; Fukata, S; Fukuhara, H; Inoue, K; Karashima, T; Komatsu, F; Kuno, T; Kuroiwa, H; Saito, M; Sawada, K; Tamura, K; Watanabe, H; Yasuda, M | 1 |
| Andrade, DR; Claudino, MA; Goncalves, TT; Janussi, SC; Krikorian, K; Mora, AG; Priviero, FBM | 1 |
| Bhojani, N; Nguyen, DD; Trinh, QD | 1 |
| Gupta, A; Kloner, RA; Kostis, JB; McGraw, TP; Qiu, C | 1 |
| Matsuo, T; Miyata, Y; Sakai, H | 1 |
| Abe, N; Ishikawa, M; Kakizaki, H; Makino, S; Miyauchi, K; Wada, N | 1 |
| Blachman-Braun, R; Goberdhan, S; Masterson, TA; Nackeeran, S; Ramasamy, R | 1 |
| Altunrende, F; Canat, L; Culha, MG; Ermec, B; Kocak, G; Otunctemur, A | 1 |
| AbdelRazek, M; Abolyosr, A; Fathi, A; Hassan, A; Mhammed, O; Talaat, M | 1 |
| Fujihara, A; Harikai, S; Hirahara, N; Ukimura, O; Ushijima, S; Yamada, Y | 1 |
| Fujimoto, K; Gotoh, D; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Torimoto, K | 1 |
| Chen, Q; Mao, Y; Tang, S; Zhou, H | 1 |
| Armin, A; Khoshdel, AR; Poopak, A; Samzadeh, M; Zahir, M | 1 |
| Araki, K; Matsuo, T; Miyata, Y; Mukae, Y; Ohba, K; Otsubo, A; Sakai, H | 1 |
| Atan, A; Bulut, EC; Doğan, AE; Polat, F; Tokuçoğlu, H; Ünsal, A; Yeşil, S | 1 |
| Kamalov, AA; Nizov, AN | 1 |
| Akamatsu, S; Goto, T; Kobayashi, T; Matsubara, K; Matsui, Y; Negoro, H; Ogawa, O; Omura, T; Terada, N; Yamamoto, T; Yonezawa, A | 1 |
| Chapple, C; De Nunzio, C; Frizzi, J; Gacci, M; Gravas, S; Kaplan, SA; Maggi, M; McVary, KT; Saleh, O; Sebastianelli, A; Serni, S; Spatafora, P; Tubaro, A; Vignozzi, L | 1 |
| Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T | 1 |
| Kaputovskij, AA | 1 |
| Wein, AJ | 2 |
| Huang, H; Huang, WP; Ye, XT; Zhang, FY | 1 |
| Cai, Z; Li, H; Ma, C; Xiong, J; Zhang, J | 1 |
| Chen, X; Guo, B; Hou, H; Liu, M; Wang, M; Zhang, Z | 1 |
| Abe, N; Kakizaki, H; Kikuchi, D; Kita, M; Tamaki, G; Tateoka, J; Wada, N; Watanabe, M | 1 |
| Jeong, TY; Kim, KS; Moon, HS | 1 |
| Gupta, S; Singh, I; Tk, A | 1 |
| Borisov, VV | 1 |
| Fujita, T; Funahashi, Y; Gotoh, M; Ishida, S; Kato, M; Matsukawa, Y; Naito, Y; Tochigi, K | 1 |
| Izumi, K; Kadono, Y; Kawaguchi, S; Mizokami, A; Nohara, T; Shigehara, K; Shimamura, M; Shouda, R | 1 |
| Chapple, C; Gacci, M; Gravas, S; Kaplan, S; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L | 1 |
| Chapple, C; Gacci, M; Gemma, L; Gravas, S; Kaplan, SA; Liaci, A; Maggi, M; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L; Zaccaro, C | 1 |
| Higashi, Y; Kuwahara, Y; Nakamura, K; Shimura, H; Takeda, M; Tsukamoto, T; Watanabe, N | 1 |
| Fukazawa, A; Hashida, I; Iijima, K; Ishizuka, O; Kato, H; Koiwai, K; Minagawa, T; Ogawa, T; Oguchi, T; Saitou, T | 1 |
| Kosivtsova, MA; Kostromeev, SA; Statsenko, ME; Turkina, SV; Tyschenko, IA | 1 |
| Kinoshita, H; Matsuda, T; Shimada, S; Taguchi, M; Yoshida, T | 1 |
| Origasa, H; Seki, N; Yoshida, M | 1 |
| Kaplan, SA | 4 |
| Ahn, TY; Hyun, JS; Jung, J; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Park, NC; Ryu, JK; Son, H; Yang, DY; Yang, SK | 1 |
| Aoki, K; Fujimoto, K; Gotoh, D; Hirayama, A; Hori, S; Miyake, M; Morizawa, Y; Tanaka, N; Tatsumi, Y; Torimoto, K; Yamada, A | 1 |
| Amano, T; Earle, C; Imao, T; Kishikage, T; Matsumoto, Y | 1 |
| Murakami, M; Ozeki, A; Suzuki, N; Yokoyama, O | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Matsuo, K; Yamamoto, T | 1 |
| Eto, M; Fujimoto, N; Mimata, H; Miyazato, M; Nishii, H; Onzuka, M; Oshiro, T; Saito, S; Sumino, Y; Takahashi, R; Takayama, K | 1 |
| Bao, Y; Cui, Y; Duan, L; Liu, J; Wang, Y | 1 |
| Burgio, G; Calogero, AE; Cannarella, R; Condorelli, RA; La Vignera, S | 1 |
| Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Sassa, N; Takai, S; Yamamoto, T | 1 |
| Griebling, TL | 1 |
| Dai, Y; Jiann, BP; Li, H; Li, P; Lou, Y; Park, HJ; Viktrup, L; Ye, Z; Zhang, X; Zhang, Z | 1 |
| Kitta, T | 1 |
| Funahashi, Y; Gotoh, M; Inoue, S; Kanada, Y; Kato, M; Majima, T; Matsukawa, Y; Takai, S; Yamamoto, T | 1 |
| Hashimoto, Y; Hatakeyama, S; Matsumoto, T; Narita, T; Ohyama, C; Yoneyama, T | 1 |
| De Nucci, G; Mónica, FZ | 1 |
| Bulygin, KV; Galimov, SN; Galimova, EF; Gaysina, GG; Nikitina, IL; Pavlov, VN | 1 |
| Yuan, RQ | 1 |
| Andersson, KE; Gratzke, C; Herlemann, A; Sievert, KD | 1 |
| Baye, J; Cantrell, MA; Vouri, SM | 1 |
| de la Taille, A; Doridot, G; Giuliano, F; Rouprêt, M | 1 |
| Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Nesi, G; Santi, R; Sebastianelli, A; Serni, S; Vignozzi, L | 1 |
| Brock, GB; Lee, KC | 1 |
| Esler, A; Porst, H; Roehrborn, CG; Secrest, RJ; Viktrup, L | 1 |
| de Groat, WC | 1 |
| Cox, D; Dey, D; Goldfischer, ER; Oelke, M; Porst, H; Viktrup, L; Watts, S | 1 |
| Brock, G; Broderick, G; Roehrborn, CG; Viktrup, L; Wong, D; Xu, L | 1 |
| Casabé, A; Da Pozzo, LF; Henderson, RJ; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L; Wong, DG; Zepeda, S | 1 |
| Brock, GB; Donatucci, C; McVary, KT; Ni, X; Roehrborn, CG; Viktrup, L; Watts, S; Wong, DG | 1 |
| Mandal, AK; Mete, UK; Singh, DV; Singh, SK | 1 |
| Bechara, A; Casabe, A; Cobreros, C; Rodriguez Baigorri, G | 1 |
| de la Rosette, JJ | 1 |
| Carson, CC; Kissel, J; Rosenberg, M; Wong, DG | 1 |
| Chapple, C; Cox, D; Esler, A; Oelke, M; Roehrborn, CG; Viktrup, L | 1 |
| Cox, D; Mamoulakis, C; Oelke, M; Ruff, D; Viktrup, L; Weiss, JP | 1 |
| Lee, SW; Morisaki, Y; Murakami, M; Takeda, M; Viktrup, L; Yokoyama, O | 1 |
| Akino, H | 1 |
| Baygani, SK; Giuliano, F; Melby, T; Oelke, M; Sontag, A | 1 |
| Bolyakov, A; Cox, D; Da Pozzo, L; Efros, M; Esler, A; Frauscher, F; Kaminetsky, J; Paduch, DA; Pinggera, GM | 1 |
| Desai, M; Ganpule, AP | 1 |
| Pinggera, GM | 1 |
| Brock, GB; Dickson, R; Henneges, C; Herschorn, S; Nickel, JC; Viktrup, L | 1 |
| Benigni, F; Briganti, A; Buono, R; Castiglione, F; Freschi, M; Hedlund, P; La Croce, G; Montorsi, F; Moschini, M; Villa, L | 1 |
| Büttner, H; Esen, A; Glina, S; Henneges, C; Plekhanov, A; Roehrborn, CG; Sorsaburu, S; Viktrup, L | 1 |
| Madersbacher, S; Schauer, I | 1 |
| Baygani, SK; Donatucci, CF; Oelke, M; Shinghal, R; Sontag, A | 1 |
| De Nunzio, C; Tubaro, A | 1 |
| Fuchikami, C; Kawai, Y; Oka, M; Oyama, T; Yoshinaga, R | 1 |
| Büttner, H; D'Anzeo, G; Fusco, F; Henneges, C; Nickel, JC; Rossi, A | 1 |
| Brock, GB; Büttner, H; Esler, A; Maggi, M; Mulhall, JP; Oelke, M; Rosenberg, MT; Vlachopoulos, C | 1 |
| Egan, KB; McVary, K; Miner, MM; Ni, X; Roehrborn, CG; Rosen, RC; Suh, M; Wittert, G; Wong, DG | 1 |
| Egan, KB; Miner, MM; Ni, X; Roehrborn, CG; Rosen, RC; Wong, DG | 1 |
| Baygani, S; Brock, GB; Donatucci, CF; Glina, S; Maggi, M; Mulhall, JP | 1 |
| Baygani, S; Clouth, J; Donatucci, CF; Henneges, C; McVary, KT; Oelke, M; Peterson, A; Wong, D | 1 |
| Fukagai, T; Hayashi, K; Igarashi, A; Koshikiya, A; Morita, M; Sasaki, H | 1 |
| Aversa, A; Cortese, A; Francomano, D; Ilacqua, A; Inghilleri, M; Lenzi, A; Tartaglia, G | 1 |
| Hikita, K; Honda, M; Kawamoto, B; Morizane, S; Muraoka, K; Sejima, T; Takenaka, A | 1 |
| Fallah-Karkan, M; Hassanzadeh-Hadad, A; Karami, H | 1 |
| Büttner, H; Oelke, M; Takita, Y; Viktrup, L; Wagg, A | 1 |
| Fujii, T; Fukumoto, K; Hara, R; Miyaji, Y; Nagai, A | 1 |
| Fukimbara, S; Odani, M; Sato, T | 1 |
| Fukagai, T; Hayashi, K; Igarashi, A; Ishikawa, K; Koshikiya, A; Morita, M; Sasaki, H | 1 |
| Madersbacher, S | 1 |
| Angalakuditi, M; Hayes, RP; O'Leary, MP; Seifert, RF; Viktrup, L | 1 |
| Casabé, AR; Kim, ED; Mirone, V; Porst, H; Secrest, RJ; Sundin, DP; Viktrup, L; Xu, L | 1 |
| Helfand, BT; Mazur, DJ; McVary, KT | 1 |
| Cox, D; Giuliano, F; Mirone, V; Oelke, M; Viktrup, L; Xu, L | 1 |
| Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA | 1 |
| Chapple, CR | 1 |
| Carini, M; Corona, G; Gacci, M; Kaplan, SA; Maggi, M; McVary, KT; Mirone, V; Roehrborn, CG; Salvi, M; Serni, S; Vignozzi, L | 1 |
| Imaoka, T; Kim, SC; Morisaki, Y; Viktrup, L; Wang, CJ; Yokoyama, O; Yoshida, M | 1 |
| Gacci, M | 1 |
| Dmochowski, R; Kaminetsky, J; Klise, S; Kraus, S; Roehrborn, C; Xu, L | 1 |
| Miller, MS | 1 |
19 review(s) available for tadalafil and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis.
Topics: Combined Modality Therapy; Erectile Dysfunction; Health Care Costs; Humans; Lower Urinary Tract Symptoms; Male; Tadalafil | 2022 |
[Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction].
Topics: Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.
Topics: Bayes Theorem; Databases, Factual; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Safety; Sildenafil Citrate; Tadalafil; Tamsulosin; Treatment Outcome | 2020 |
Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials.
Topics: Adrenergic alpha-1 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperplasia; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Tadalafil; Tamsulosin; Treatment Outcome | 2020 |
Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED.
Topics: Combined Modality Therapy; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents | 2020 |
Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Severity of Illness Index; Tadalafil | 2018 |
Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2018 |
Tadalafil for the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Animals; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome | 2019 |
[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; Treatment Outcome | 2012 |
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Topics: Carbolines; Controlled Clinical Trials as Topic; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Urodynamics; Vardenafil Dihydrochloride | 2013 |
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
Topics: Carbolines; Drug Approval; Erectile Dysfunction; Half-Life; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; United States; United States Food and Drug Administration | 2013 |
[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Daily dosing of PDE5 inhibitors: where does it fit in?
Topics: Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2013 |
Tadalafil - a therapeutic option in the management of BPH-LUTS.
Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Multicenter Studies as Topic; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Urodynamics; Urological Agents | 2014 |
Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Tadalafil; Urological Agents | 2015 |
Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment.
Topics: Acetylcholine Release Inhibitors; Botulinum Toxins, Type A; Drug Combinations; Humans; Laser Therapy; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Solifenacin Succinate; Sulfonamides; Tadalafil; Tamsulosin; Transurethral Resection of Prostate; Urological Agents | 2015 |
Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Carbolines; Disease Progression; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Men's Health; Middle Aged; Neurotransmitter Agents; Piperazines; Prognosis; Prostatic Hyperplasia; Purines; Receptors, Neurotransmitter; Risk Assessment; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2012 |
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2012 |
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Resistance; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostate; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2013 |
41 trial(s) available for tadalafil and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Editorial Comment to Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double-blinded, randomized, pilot clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Herbal Medicine; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Treatment Outcome | 2022 |
Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Topics: Erectile Dysfunction; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome | 2022 |
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial.
Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Sildenafil Citrate; Tadalafil; Treatment Outcome; Urinary Retention | 2023 |
Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Humans; Lower Urinary Tract Symptoms; Male; Oxidative Stress; Prospective Studies; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2020 |
The efficacy of Tadalafil 5mg in the treatment of lower urinary tract symptoms in patients where alpha blocker treatments have failed in terms of lower urinary tract symptoms.
Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2019 |
Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents | 2020 |
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents | 2020 |
[Therapeutic effect of tadalafil on lower urinary tract symptoms with erectile dysfunction].
Topics: Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Treatment Outcome | 2019 |
Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents | 2020 |
Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Resistance; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Pelvic Pain; Plant Extracts; Pollen; Prospective Studies; Prostatitis; Tadalafil; Treatment Outcome; Urodynamics | 2020 |
Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
Topics: Brachytherapy; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfonamides; Tadalafil; Treatment Outcome | 2021 |
Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Topics: Aged; Drug Administration Schedule; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urological Agents | 2017 |
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Topics: Aged; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents | 2017 |
Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
Topics: Aged; Aged, 80 and over; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urination; Urodynamics | 2018 |
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled s
Topics: Aged; China; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Republic of Korea; Severity of Illness Index; Tadalafil; Taiwan; Tamsulosin; Treatment Outcome | 2019 |
Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study.
Topics: 5-alpha Reductase Inhibitors; Aged; Dose-Response Relationship, Drug; Drug Substitution; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Severity of Illness Index; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome | 2019 |
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
Topics: Aged; Aged, 80 and over; Carbolines; Cyclic GMP; Double-Blind Method; Humans; Imidazoles; Inflammation; Interleukin-8; Lower Urinary Tract Symptoms; Male; Middle Aged; Myofibroblasts; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Prostate; Prostatic Hyperplasia; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2013 |
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical stu
Topics: Aged; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Tadalafil; Urination | 2013 |
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Back Pain; Carbolines; Dyspepsia; Headache; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nasopharyngitis; Organ Size; Phosphodiesterase 5 Inhibitors; Prostate; Prostate-Specific Antigen; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Tadalafil; Testosterone | 2013 |
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2013 |
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urological Agents | 2014 |
A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urinary Retention | 2014 |
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Carbolines; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Urination | 2014 |
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies.
Topics: Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2014 |
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
Topics: Aged; Asian People; Carbolines; Double-Blind Method; Humans; Japan; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Republic of Korea; Tadalafil; Treatment Outcome | 2014 |
Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents | 2014 |
Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial.
Topics: Aged; Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Regional Blood Flow; Tadalafil | 2014 |
Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants.
Topics: Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Remission Induction; Tadalafil | 2015 |
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Topics: Carbolines; Coitus; Comorbidity; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2015 |
Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.
Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Remission Induction; Tadalafil; Time Factors | 2015 |
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Risk Factors; Tadalafil; Vasodilator Agents | 2015 |
Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Topics: Aged; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Tria
Topics: Adult; Aged; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Testosterone; Treatment Outcome; Vasodilator Agents | 2016 |
Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperpl
Topics: Aged; Dose-Response Relationship, Drug; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urination | 2016 |
Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Single-Blind Method; Sulfonamides; Tadalafil; Tamsulosin | 2016 |
Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.
Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Sickness Impact Profile; Statistics, Nonparametric; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome | 2010 |
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Topics: Aged; Analysis of Variance; Argentina; Carbolines; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Lower Urinary Tract Symptoms; Male; Mexico; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Tadalafil; Time Factors; Treatment Outcome; United States; Urination; Urodynamics | 2011 |
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Vasodilator Agents | 2012 |
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Double-Blind Method; Doxazosin; Hemodynamics; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2012 |
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Topics: Administration, Oral; Aged; Analysis of Variance; Carbolines; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Selection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Reference Values; Risk Assessment; Severity of Illness Index; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urination; Urodynamics | 2013 |
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Time Factors; Urodynamics | 2013 |
57 other study(ies) available for tadalafil and Lower Urinary Tract Symptom
| Article | Year |
|---|---|
Tadalafil 5 mg Once Daily Improved Each IPSS Subscore, QOL, and Nocturia in Elderly BPH Patients over 70 Years Old in a Real-World Clinical Setting.
Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Nocturia; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome | 2022 |
Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure.
Topics: Animals; Heart Failure; Kidney; Lower Urinary Tract Symptoms; Male; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder | 2022 |
Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade.
Topics: Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Tract | 2022 |
Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.
Topics: Antihypertensive Agents; Double-Blind Method; Erectile Dysfunction; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome | 2022 |
Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome | 2022 |
Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?
Topics: Adrenergic alpha-Antagonists; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Venous Thromboembolism | 2022 |
The effect of vitamin D replacement in patients with lower urinary tract complaint/erectile dysfunction resistant to Tadalafil 5 mg treatment: A pilot clinical study.
Topics: Adult; Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Tract; Vitamin D; Vitamins | 2022 |
Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms.
Topics: Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive | 2022 |
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urinary Bladder, Overactive | 2022 |
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction].
Topics: Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Moscow; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome | 2019 |
Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Urological Agents | 2021 |
Re: Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
Topics: Humans; Lower Urinary Tract Symptoms; Male; Oxidative Stress; Tadalafil; Urinary Bladder, Overactive; Urological Agents | 2020 |
Persistence Rate with Tadalafil for Treatment of Male Lower Urinary Tract Symptoms.
Topics: Aged; Aged, 80 and over; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Retrospective Studies; Tadalafil; Withholding Treatment | 2020 |
Re: Effect of Tadalafil 5 mg on Post-Micturition Dribble in Men with Lower Urinary Tract Symptoms: A Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Tadalafil; Urinary Tract; Urination | 2020 |
Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms: STROBE, a case-control study.
Topics: Adult; Aged; Case-Control Studies; Depression; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Tadalafil; Young Adult | 2020 |
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study].
Topics: Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Moscow; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2020 |
[Effects of Tadalafil 5 mg Once-Daily on Serum Testosterone Level, Erectile Function, and Highly Sensitive C-Reactive Protein Value in Hypogonadal Patients with Lower Urinary Tract Symptoms].
Topics: C-Reactive Protein; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Testosterone; Treatment Outcome | 2020 |
Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome.
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin | 2021 |
[EVALUATING THE RELATIONSHIP BETWEEN LOWER URINARY TRACT SYMPTOMS AND ENDOTHELIAL FUNCTION USING FLOW-MEDIATED DILATION, AND THE EFFECTS OF TADALAFIL].
Topics: Aged; Blood Flow Velocity; Endothelium, Vascular; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Vasodilation | 2020 |
[Effect of Tadalafil SZ on endothelial function in patients with erectile dysfunction].
Topics: Adult; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2021 |
Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; Treatment Outcome; Urination | 2017 |
Re: Do Baseline Estrogen and Testosterone Affect Lower Urinary Tract Symptoms (LUTS) Prior to or after Pharmacologic Treatment with Tadalafil?
Topics: Estrogens; Humans; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Tadalafil; Testosterone | 2017 |
Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Tadalafil; Urethra; Urinary Bladder | 2018 |
Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
Topics: Aged; Ankle Brachial Index; Endothelium, Vascular; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostate; Prostatic Hyperplasia; Pulse Wave Analysis; Tadalafil | 2018 |
Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
Topics: Humans; Japan; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prognosis; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Tadalafil; Treatment Outcome; Urination | 2018 |
Re: A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-Analysis.
Topics: Humans; Lower Urinary Tract Symptoms; Male; Placebo Effect; Prostatic Hyperplasia; Tadalafil; Urinary Bladder | 2017 |
Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Topics: Aged; Aged, 80 and over; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Symptom Assessment; Tadalafil; Urination; Urodynamics | 2018 |
Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study.
Topics: Aged; Aged, 80 and over; Animals; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urodynamics; Urological Agents | 2019 |
Re: Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 Years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-Controlled
Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2018 |
Re: Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin | 2018 |
Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and ta
Topics: Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin | 2019 |
Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction.
Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Testosterone; Urinary Bladder Neck Obstruction; Urodynamics | 2020 |
[Safety of tadalafil in patients with cardiovascular comorbidities].
Topics: Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2019 |
Lower urinary tract dysfunction: From basic science to clinical management. Foreword.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Afferent Pathways; Biomarkers; Botulinum Toxins; Carbolines; Humans; Lower Urinary Tract Symptoms; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Thiazoles; Urinary Bladder, Overactive; Urothelium | 2013 |
Tadalafil for benign prostatic hyperplasia.
Topics: Adult; Carbolines; Drug Approval; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2013 |
Should you take an erectile dysfunction drug to also ease urinary woes? We think not. Standard medications to treat the symptoms of an enlarged prostate are still the best first choice for men.
Topics: Aged; Aged, 80 and over; Carbolines; Ejaculation; Erectile Dysfunction; Evidence-Based Medicine; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2013 |
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Topics: Aged; Carbolines; Comorbidity; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2014 |
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2014 |
Lower urinary tract symptoms in the elderly male: choosing wisely.
Topics: Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Tadalafil | 2014 |
Editorial comment to Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2014 |
Editorial comment.
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostate; Regional Blood Flow; Tadalafil | 2014 |
Reply: To PMID 24938580.
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostate; Regional Blood Flow; Tadalafil | 2014 |
Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Animals; Carbolines; Drug Synergism; Electric Stimulation; Erectile Dysfunction; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Muscle Contraction; Phenylephrine; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Tadalafil | 2014 |
Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release.
Topics: Animals; Aorta, Abdominal; Constriction; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Iliac Artery; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostate; Rats; Seminal Vesicles; Tadalafil; Urinary Bladder; Urinary Tract | 2015 |
Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.
Topics: Aged; Data Mining; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Precision Medicine; Prognosis; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil | 2015 |
Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
Topics: Aged; Biomarkers; Cross-Sectional Studies; Databases, Factual; Estradiol; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Predictive Value of Tests; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Testosterone; Time Factors; Treatment Outcome | 2015 |
[A Study of the Efficacy of the Additional Administration of Tadalafil in Japanese Men with α1-Blocker-Resistant LUTS/BPH].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Asian People; Drug Resistance; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome; Urodynamics | 2016 |
Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Compari
Topics: Double-Blind Method; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Personal Satisfaction; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2016 |
Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study.
Topics: Adult; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Multiple Sclerosis; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prognosis; Prospective Studies; Single-Blind Method; Tadalafil | 2017 |
Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.
Topics: Aged; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Postoperative Care; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence | 2017 |
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled cli
Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome | 2017 |
Tadalafil for male lower urinary tract symptoms improves endothelial function.
Topics: Aged; Ankle Brachial Index; Endothelium, Vascular; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Pulse Wave Analysis; Quality of Life; Tadalafil; Ultrasonography; Urination; Urodynamics; Vasodilator Agents | 2017 |
A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
Topics: Bayes Theorem; Drug-Related Side Effects and Adverse Reactions; Humans; Lower Urinary Tract Symptoms; Male; Meta-Analysis as Topic; Models, Statistical; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil | 2017 |
EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urodynamics | 2016 |
Re: Efficacy and Safety of Tadalafil 5mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-controlled
Topics: Aged; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome | 2017 |
Monotherapy with α-blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms?
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Vasodilator Agents | 2012 |
Editorial Comment to tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin | 2013 |